CRISPR Therapeutics AG (CRSP) Profit After Tax (2015 - 2026)

CRISPR Therapeutics AG has reported Profit After Tax for 12 years, with the latest figure at -$129.7 million in Q1 2026.

• Quarterly Profit After Tax rose 3.0% year-over-year to -$129.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$572.3 million (down 51.18% YoY) and the FY2025 annual result came in at -$578.6 million, down 57.98% from the prior year.
• Profit After Tax eased to -$129.7 million in Q1 2026 per CRSP's latest filing, from -$127.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at $89.3 million in Q4 2023 and troughed at -$208.5 million in Q2 2025.
• A 5-year average of -$109.7 million and a median of -$116.6 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2025: Profit After Tax surged 185.94% in 2023, then plunged 177.68% in 2025.
• Over 5 years, Profit After Tax stood at -$104.0 million in 2022, then soared by 185.94% to $89.3 million in 2023, then plunged by 151.44% to -$46.0 million in 2024, then tumbled by 177.68% to -$127.6 million in 2025, then fell by 1.61% to -$129.7 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$129.7 million, -$127.6 million, and -$106.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.